Affymetrix Announces That PE Corporation Has Filed Suit Against Affymetrix on Chemical Synthesis Patents
SANTA CLARA, Calif., July 6 /PRNewswire/ -- Affymetrix, Inc. (Nasdaq: AFFX) announced that PE Corporation (NYSE: PEB) filed suit in the Federal District Court in Delaware based on several patents related to reagents Affymetrix purchases from PE licensed vendors.
"Affymetrix purchases its reagents from licensed vendors, therefore, we believe we have meritorious defenses to the claims in this lawsuit," said Vern Norviel, Senior Vice President and General Counsel of Affymetrix.
Affymetrix is a leader in developing and commercializing systems to acquire, analyze and manage complex genetic information in order to improve the quality of life. The Company's GeneChip(R) system consists of disposable DNA probe arrays containing gene sequences on a chip, reagents for use with the probe arrays, a scanner, and other instruments to process the probe arrays and software to analyze and manage genetic information. The Company's spotted array system enables individual researchers to create and analyze custom microarrays on an easy-to-use, cost efficient platform. Additional information on Affymetrix and GeneChip technology can be found at www.affymetrix.com.
All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies" or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to, uncertainties relating to technological approaches, product development, manufacturing, market acceptance, uncertainties related to cost and pricing of Affymetrix products, dependence on collaborative partners, uncertainties relating to sole source suppliers, uncertainties relating to FDA and other regulatory approvals, competition, risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix' Annual Report on Form 10-K for the year ended December 31, 1999. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix' expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. Affymetrix, GeneChip and the Affymetrix logo are registered trademarks used by Affymetrix, Inc.
SOURCE Affymetrix, Inc.
CO: Affymetrix, Inc.; PE Corporation
ST: California, Delaware
IN: MTC BIO
SU: LAW
07/06/2000 09:01 EDT prnewswire.com |
